|
Novo launches a new treatment type 2 diabetes
Mr Cihan Serdar Kicilzik, General Manager, Novo Thailand said Novo launches a higher dose Semaglutide treatment option in Thailand for adults with type 2 diabetes. With the new treatment option, Novo urges people living with type 2 diabetes to look beyond blood sugar and consult healthcare professionals.
The new therapy addresses the cardiovascular–kidney–metabolic (CKM) syndrome, reflecting Novo’s commitment to holistic care for a condition affecting millions of Thai populations.
The prevalence of type 2 diabetes in Thailand in 2025 is at 10.6 percent—an increase from 9.5 percent in the last survey in 2020. Yet many people living with the condition — and their families — are unaware that diabetes is closely linked to some of the most serious health threats facing Thai society today. Research and development have transformed what is possible in type 2 diabetes care. A new generation of therapies has demonstrated benefits that extend beyond blood sugar control, including improvements in body weight and reductions in the risk of major cardiovascular and kidney-related events.
As part of this evolution, Novo has introduced in Thailand a new, higher dose Semaglutide treatment option for adults living with type 2 diabetes. The therapy reflects the company’s continued investment in innovation for people living with diabetes and other serious chronic diseases. Decisions on the most appropriate treatment should always be made between a patient and their healthcare professional. At Novo, our purpose is lasting health starts now, and that means encouraging people to start looking beyond blood sugar alone and to speak openly with their doctors about their holistic health conditions, including heart and kidney health.
We are proud to have worked with the diabetes community in Thailand for more than 40 years, and we remain committed to advancing science, raising awareness and working alongside healthcare professionals, patient groups and authorities to help every person living with type 2 diabetes live a longer, healthier life.”
Go To Lead
|
